Clinigen Group acquires oncology support product from Novartis

AIM-listed pharmaceutical products and services business Clinigen Group has acquired Cardioxane (dexrazoxane) from Novartis for 33m dollars in cash, payable in two tranches.

AIM-listed pharmaceutical products and services business Clinigen Group has acquired Cardioxane (dexrazoxane) from Novartis for 33m dollars in cash, payable in two tranches.

Under the terms of the agreement, Clinigen will assume responsibility for manufacturing, registration, distribution, and commercialization of the product in countries where current marketing authorizations exist. This includes European, Asian and Latin American territories.

Cardioxane, an oncology support therapy, is a cardioprotective agent used to prevent the cardiotoxicity of anthracycline chemotherapy for patients with advanced and/or metastatic breast cancer.

According to Clinigen, there is an opportunity to revitalize Cardioxane- which it said has no direct licensed competition in the anthracycline therapy cardioprotection space- by utilizing new commercialization, market and indication strategies over the next five years.

The group said that historic revenues for Cardioxane have been approximately $11-12m per annum. Clinigen is targeting a gross margin of 60%.

Latin America seen as strong marketAccording to the group, Latin America is a strong market for Cardioxane, and is of particular interest to Clinigen, because it is a territory in which the group wishes to expand its reach and which may improve access routes for existing portfolio products such as Foscavir, as well as products that Clinigen may acquire in the future.

Peter George, Chief Executive Officer of Clinigen, said: "Acquiring Cardioxane from Novartis is another major step forward for us".

He added: "Cardioxane fits particularly well within our portfolio. We have been looking for medicines that complement Foscavir and Cardioxane does this by extending our role in oncology support. Together with our recent addition of VIBATIV, which further builds on our anti-infective capability, we are delivering on our mission to supply the right drug to the right patient at the right time."

Clinigen Group's share price was up 7.59% to 255p at 14:36 on Tuesday.

MF

Recommended

Best junior stocks and shares ISA platforms
Isas

Best junior stocks and shares ISA platforms

A junior stocks and shares ISA is a great way to save for your child tax-efficiently. But it can be confusing deciding which investment platform to ch…
28 Mar 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into
2 Mar 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
27 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023

Most Popular

11 investment trusts for inflationary times
Investments

11 investment trusts for inflationary times

Inflation eats away at the value of your money, but these investment trusts can help you grow your wealth.
28 Mar 2023
Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Ofgem’s price cap is now predicted to fall below £2,000, based on average typical use, from July, for the first time since 2022. We have all the detai…
21 Mar 2023
This contrarian indicator suggests we’re at the bottom of the mining cycle
Commodities

This contrarian indicator suggests we’re at the bottom of the mining cycle

Mining might be a boring industry, but investors shouldn’t ignore it, says Dominic Frisby.
29 Mar 2023